ArticleMedicine2025
Glutamine and allergic rhinitis: A bidirectional two-sample Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glutamine (Gln) has been implicated as a potential protective factor against allergic rhinitis (AR), with supplementation studies suggesting improved patient prognosis. However, the precise relationship between circulating Gln levels and AR risk remains unclear. To address this, we employed bidirectional two-sample Mendelian randomization (MR) analysis to investigate the causal association between Gln and AR. Genome-wide association study (GWAS) summary statistics for AR (FinnGen dataset finn-b-ALLERGY_RHINITIS; 217,914 samples; 16,380,461 single nucleotide polymorphisms [SNPs]) and circulating Gln levels (met-d-Gln; 114,750 samples; 12,321,875 SNPs) were obtained from the Integrative Epidemiology Unit Open GWAS database. MR analyses were performed, primarily using the inverse variance weighted (IVW; fixed-effects) method. Sensitivity analyses included the weighted median, simple median, MR-Egger, and maximum likelihood methods. Robustness of the MR findings was further assessed via heterogeneity tests, horizontal pleiotropy evaluation (MR-Egger intercept test), and leave-one-out (LOO) analysis. Additionally, phenotypic association scanning was conducted for both AR and Gln. Forward MR (Gln→AR) revealed a significant negative causal association, identifying Gln as a protective factor for AR (IVW OR < 1; P < .05). Reverse MR (AR→Gln) showed no causal effect (P > .05). Sensitivity analyses confirmed reliability: no significant heterogeneity (Q_P > .05) or horizontal pleiotropy (P > .05) was detected in either direction, and LOO analysis supported result stability. Phenotypic scanning corroborated Gln as a protective factor against AR (OR = 0.874, 95% CI = 0.77047-0.99093, P = .036). Our study suggests that Gln is a protective factor against AR and that AR is not causally associated with Gln.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.